; and (iii) the net price of such prescription drug, after accounting for discounts, rebates, or other financial considerations, charged or planned to be charged to purchasers in each applicable prescription drug reference country, as defined in this Act. (C) The estimated annual profit and revenue that will be generated by the prescription drug, both domestically and globally. (D) Other information as the Director may require. (b) Review of certain price increases (1) In general The Bureau shall conduct a review of the price of a prescription drug for which a submission is required under paragraph (2). (2) Notification of intention to increase price If a manufacturer intends to increase the wholesale acquisition cost of a prescription drug by more than the percentage by which the Consumer Price Index for All Urban Consumers for that year exceeds such index for the preceding calendar year, such manufacturer, not later than 60 days before the price increase takes effect, shall submit to the Bureau the following information: (A) The information described in subsection (a)(2)(A). (B) The planned increase in the wholesale acquisition cost and the planned date the increase will go into effect. (C) A justification of the planned increase in wholesale acquisition cost. (D) Any other information as the Secretary may require. (c) Revenue benchmark review (1) In general The Bureau shall conduct a review of a prescription drug when revenue for such prescription drug surpasses the revenue benchmark in order to ensure that the wholesale acquisition cost of the prescription drug remains appropriate. (2) Required submission Not later than 60 days before the manufacturer of a prescription drug anticipates the global revenue for such drug will surpass the revenue benchmark, the manufacturer shall submit to the Bureau the information outlined in subsection (a)(2)(A). (3) Revenue benchmark (A) In general Subject to subparagraph (B), for purposes of this subsection, the revenue benchmark is $5,000,000,000 in global revenue. (B)